Perturbations in the MAPK pathway, particularly mutations in KRAS, NRAS, and BRAF, are observed in a significant percentage of MM cases, with RAS mutations detected in up to 70% of relapsed/refractory cases (64). The gene discussed is NRAS; the disease is Miyoshi myopathy.